Beximco Pharmaceuticals Limited
Beximco Pharmaceuticals PLC. manufactures and markets generic pharmaceutical formulations and active pharmaceutical ingredients in Bangladesh. The company provides allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskelet… Read more
Beximco Pharmaceuticals Limited (BXP) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2024: 0.019x
Based on the latest financial reports, Beximco Pharmaceuticals Limited (BXP) has a cash flow conversion efficiency ratio of 0.019x as of December 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX1.04 Billion) by net assets (GBX53.63 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Beximco Pharmaceuticals Limited - Cash Flow Conversion Efficiency Trend (2005–2024)
This chart illustrates how Beximco Pharmaceuticals Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Beximco Pharmaceuticals Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Beximco Pharmaceuticals Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Eolus Vind AB
STU:7EVB
|
-0.346x |
|
HENGAN INTL GRP
MU:HGNC
|
N/A |
|
Lee Ku Industrial Co. Ltd.
KQ:025820
|
N/A |
|
Hansol Technics Co. Ltd.
KQ:004710
|
N/A |
|
Caspian Services Inc
PINK:CSSV
|
0.004x |
|
JOPA3F
SA:JOPA3F
|
N/A |
|
SOGEFI
BE:GEF
|
0.089x |
|
NIOX Group PLC
LSE:NIOX
|
0.109x |
Annual Cash Flow Conversion Efficiency for Beximco Pharmaceuticals Limited (2005–2024)
The table below shows the annual cash flow conversion efficiency of Beximco Pharmaceuticals Limited from 2005 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-06-30 | GBX51.90 Billion | GBX8.36 Billion | 0.161x | +26.12% |
| 2023-06-30 | GBX47.62 Billion | GBX6.08 Billion | 0.128x | +3.83% |
| 2022-06-30 | GBX44.64 Billion | GBX5.49 Billion | 0.123x | -23.65% |
| 2021-06-30 | GBX37.36 Billion | GBX6.02 Billion | 0.161x | -4.61% |
| 2020-06-30 | GBX32.80 Billion | GBX5.54 Billion | 0.169x | +70.51% |
| 2019-06-30 | GBX29.86 Billion | GBX2.96 Billion | 0.099x | +49.02% |
| 2018-06-30 | GBX27.35 Billion | GBX1.82 Billion | 0.067x | -36.69% |
| 2017-06-30 | GBX25.07 Billion | GBX2.63 Billion | 0.105x | +14.65% |
| 2016-06-30 | GBX23.06 Billion | GBX2.11 Billion | 0.092x | -2.52% |
| 2015-12-31 | GBX22.48 Billion | GBX2.11 Billion | 0.094x | -11.26% |
| 2014-12-31 | GBX20.92 Billion | GBX2.22 Billion | 0.106x | -1.67% |
| 2013-12-31 | GBX19.78 Billion | GBX2.13 Billion | 0.108x | +6.76% |
| 2012-12-31 | GBX18.41 Billion | GBX1.86 Billion | 0.101x | +38.70% |
| 2011-12-31 | GBX17.13 Billion | GBX1.25 Billion | 0.073x | -3.04% |
| 2010-12-31 | GBX15.97 Billion | GBX1.20 Billion | 0.075x | +56.80% |
| 2009-12-31 | GBX10.89 Billion | GBX520.89 Million | 0.048x | -43.23% |
| 2008-12-31 | GBX10.45 Billion | GBX880.78 Million | 0.084x | +104.13% |
| 2007-12-31 | GBX8.25 Billion | GBX340.67 Million | 0.041x | -69.60% |
| 2006-12-31 | GBX7.95 Billion | GBX1.08 Billion | 0.136x | +197.37% |
| 2005-12-31 | GBX6.82 Billion | GBX311.49 Million | 0.046x | -- |